Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

yttrium Y 90 clivatuzumab tetraxetan

A radioimmunoconjugate comprised of the humanized monoclonal antibody HuPAM4, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, selectively delivering a cytotoxic dose of beta radiation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	90Y-hPAM4 hPAM4-DOTA yttrium Y 90 DOTA monoclonal antibody HuPAM4
Abbreviation:	Y90 DOTA MOAB HuPAM4
Code name:	IMMU-107

yttrium Y 90 clivatuzumab tetraxetan

Search NCI's Drug Dictionary